newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

  • FDA accepted Cogent Biosciences' NDA for bezuclastinib + sunitinib in GIST patients with Priority Review & PDUFA date set for November 30, 2026.
  • Previous Breakthrough Therapy Designation & Real-Time Oncology Review status built upon Phase 3 PEAK results leading to this acceptance.
  • FDA indicated no plan to hold an advisory committee meeting nor identified any potential review issues.
  • Bezuclastinib combination is the first treatment to show statistically significant advantage over active comparator sunitinib in GIST patients.
  • PEAK trial demonstrated median PFS of 16.5 months for bezuclastinib combination versus 9.2 months for sunitinib alone (HR=0.50, p<0.0001).
  • Objective response rate was 46% for bezuclastinib combination versus 26% for sunitinib in imatinib-resistant patients.
  • Full Phase 3 PEAK results to be presented in an oral session at ASCO on May 30, 2026, in Chicago.
  • Safety data shows the combination was generally well-tolerated with no unique risks compared to sunitinib monotherapy.
  • Most common Grade 3+ adverse events included hypertension, neutropenia, ALT/AST increased, anemia, & diarrhea.
  • 7.4% of patients on the combination discontinued due to adverse events compared to 3.8% on sunitinib alone.
  • ALT/AST elevations led to bezuclastinib dose reductions in 12.7% of patients, with only 1.5% discontinuing due to these events.
  • All Grade 3 ALT/AST elevations resolved with no Grade 4 elevations reported.
  • Cogent established Expanded Access Programs (EAPs) for U.S. patients with GIST or systemic mastocytosis to access bezuclastinib.
  • Company anticipates expected bezuclastinib launches in GIST & systemic mastocytosis later in 2026.